Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2020-04-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事候选人声明（侯欣一）
Regulatory Filings
2020-04-28 Chinese
独立董事关于提名第十届董事会董事候选人的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the nomination of candidates for the company's 10th board of directors. It references governance rules and qualifications for board membership. This type of document is related to board or management information, specifically announcements or opinions about changes or nominations in the company's board of directors. It is not a full annual report, audit report, or financial statement. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and focused on board nominations, confirming this classification.
2020-04-28 Chinese
2020年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled '2020 年第一季度报告' which translates to '2020 First Quarter Report'. It contains detailed financial data including balance sheet items, profit and loss items, cash flow items, and explanations of changes compared to the previous year. The document is comprehensive and includes actual financial statements and analysis for the first quarter of 2020. It is explicitly stated that this is a quarterly report and it is unaudited. The length of the document (5702 characters) and the detailed financial content confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2020-04-28 Chinese
关于变更注册资本及修订公司章程的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding changes to its registered capital and amendments to its articles of association (company bylaws). It details the repurchase and cancellation of restricted shares, the resulting decrease in registered capital, and specific revisions to the company's charter. The document is a formal public announcement to shareholders and the market about these corporate governance and capital structure changes. It does not contain full financial statements or comprehensive financial performance data, nor is it a report or presentation. It is not a notice of dividend, nor a voting result declaration. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about corporate changes that do not fit into more specific categories like capital changes (SHA) or management changes (MANG). Although it involves capital changes, the primary focus is on the announcement of the capital change and charter amendments, not the issuance or new share issuance event itself. The document length is short (1909 characters), consistent with an announcement rather than a full report.
2020-04-28 Chinese
2019年度关于上海傲源医疗用品有限公司原股东业绩承诺实现情况的专项审核报告
Regulatory Filings
2020-04-28 Chinese
关于召开2019年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2019 Annual General Meeting (AGM) of the company 中源协和细胞基因工程股份有限公司. It includes details such as the date and location of the meeting, voting methods, agenda items to be discussed and voted on, and instructions for shareholders to attend and vote. The document does not contain the actual annual report or financial statements but rather informs shareholders about the meeting where such reports will be presented and voted upon. The document length is 4257 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2020-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.